Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Overzicht 
Dr. Mark A. Goldberg, MD, is an Independent Director at Blueprint Medicines Corp., an Independent Director at GlycoMimetics, Inc., an Independent Director at Idera Pharmaceuticals, Inc. and an Independent Director at ImmunoGen, Inc.

He is on the Board of Directors at Avacta Group Plc, Blueprint Medicines Corp., GlycoMimetics, Inc., Idera Pharmaceuticals, Inc., ImmunoGen, Inc. and American Cancer Society New England Division, Inc. Dr. Goldberg was previously employed as an Independent Director by Audentes Therapeutics, Inc., a Chief Medical Officer by CANbridge Life Sciences Ltd., an Executive VP-Global Medical & Regulatory Strategy by Synageva BioPharma Corp., a Senior Vice President-Clinical Research by Genzyme Corp., an Associate Professor by Harvard Medical School, a Principal by The Brigham & Women's Hospital, Inc., and a Principal by Dana-Farber Cancer Institute, Inc.

He also served on the board at aTyr Pharma, Inc.

He received his undergraduate degree from Harvard College and a doctorate degree from Harvard Medical School.


Posities en verantwoordelijkheden van Mark Alan Goldberg 
NaamTitel Van
Blueprint Medicines Corporation
(Biotechnologie & Medisch Onderzoek)
Independent Director 2015
ImmunoGen, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2011
Avacta Group Plc
(Biotechnologie & Medisch Onderzoek)
Non-Executive Director 2021
GlycoMimetics, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2014
Idera Pharmaceuticals, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2014
American Cancer Society New England Division, Inc. Director 2019


Belangnemingen van Mark Alan Goldberg 
NaamAandelen%Totale waarde
Blueprint Medicines Corporation (BPMC)
(Biotechnologie & Medisch Onderzoek)
5 8120,0099%542 085 USD
ImmunoGen, Inc. (IMGN)
(Biotechnologie & Medisch Onderzoek)
53 8000,027%325 490 USD
Idera Pharmaceuticals, Inc. (IDRA)
(Biotechnologie & Medisch Onderzoek)
48 6100,092%52 985 USD
GlycoMimetics, Inc. (GLYC)
(Biotechnologie & Medisch Onderzoek)
16 7470,032%37 178 USD


Mark Alan GoldbergPersoonlijk netwerk 
Meest gelezen nieuws 
22/09WILLIAM ACKMAN : Ackman's Pershing Square fonds stijgt bij beursdebuut Universal
MR
24/09CATHIE WOOD : Chinese maatregelen tegen bitcoin opnieuw een klap voor Cathie Woods ARK ETF
MR
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Mark Alan Goldberg Verbindingen